TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

Abstract

BACKGROUND: could be included in the molecular profile under consideration. AIM: mutations with survival of CRC patients treated with chemotherapy. METHODS: polymorphisms Similarly, based on 3'UTR polymorphism ins/loss of heterozygosity (LOH) patients were allocated into two groups (high and low risk of relapse, respectively). Cox regression models examined the associated 5-year survival outcomes. RESULTS: (39% of patients) not. CONCLUSION: may indicate patients at lower risk of relapse following adjuvant chemotherapy.